SEC Form 4 · accession 0001104659-15-025547
Mylan N.V. · MYL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, nominal value euro 0.01 per share | Mar 31, 2015 | J | 35,000,000 | $56.8912 | D | 75,000,000 | I | By Subsidiaries |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Call Option (Obligation to Sell) | $56.8912 | Mar 31, 2015 | J | 1 | D | Mar 31, 2015 | Apr 30, 2015 | Ordinary Shares | 5,250,000 | 1 | I |
Remarks
The Ordinary Shares of Mylan N.V. ("Mylan") described in this report are held directly by Laboratoires Fournier S.A.S., Abbott Established Products Holdings (Gibraltar) Limited and Abbott Investments Luxembourg S.a r.l (collectively, the "Subsidiaries"). Each of the Subsidiaries is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of the Subsidiaries, Abbott may be deemed to indirectly beneficially own such Ordinary Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. On March 31, 2015, the Subsidiaries entered into an Underwriting Agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC and Goldman Sachs & Co., as representatives of the several underwriters named therein, and Mylan relating to an underwritten public resale offering by the Subsidiaries of an aggregate of 35,000,000 Ordinary Shares. The purchase price to be received by the Subsidiaries pursuant to the Underwriting Agreement is $56.89125 per Ordinary Share. Pursuant to the Underwriting Agreement, Abbott Investments Luxembourg S.a r.l, for no additional consideration, granted the underwriters a 30-day option to purchase up to an additional 5,250,000 Ordinary Shares at the same price per Ordinary Share.